Stocks to Watch: Intel, Deckers, Edwards Lifesciences, Genmab
By Elias Schisgall
Intel's second-quarter results well exceeded Wall Street expectations, and the company lifted its 2026 capital expenditures outlook for the year. Shares initially rallied after the bell, at one point gaining more than 10%, and were up 3.5% to $103.75 as of Thursday evening.
Deckers Outdoor's lifted its profit outlook and reported higher first-quarter sales, boosted by growth in its two biggest brands. Still, shares fell 4.8% to $91.65 in after-hours trading.
Edwards Lifesciences reported double-digit revenue growth in the second quarter and lifted the bottom end of its guidance. The stock was up 3.9% to $83.82 after the bell.
A lymphoma drug co-developed by Genmab and AbbVie failed to meet its primary endpoint in a Phase 3 trial. Genmab American Depositary Receipts fell 4% to $28.00.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
July 23, 2026 19:31 ET (23:31 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The 7 Best Dividend Aristocrats to Buy Now for the Long Term
The 10 Best Companies to Invest in Now
7 Stocks to Buy That Can Move the Market
This Turnaround Stock Is Up and Still 38% Undervalued
United States